While there's little disagreement that speeding drug approvals would be a good thing, there are more questions than answers ...

Peter Marks, who headed the FDA’s Center for Biologics Evaluation and Research before being forced to resign in March, said the agency’s new risk-based COVID-19 vaccine framework contradicts the ...

Myocarditis, a type of heart inflammation that is usually mild, emerged as a rare effect with the first COVID-19 shots.